NRX Pharmaceuticals
NRXP
32 hedge funds and large institutions have $4.78M invested in NRX Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 4 closing their positions.
1,133% more call options, than puts
Call options by funds: $74K | Put options by funds: $6K
131% more capital invested
Capital invested by funds: $2.07M → $4.78M (+$2.71M)
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
7% more funds holding
Funds holding: 30 → 32 (+2)
0.97% more ownership
Funds ownership: 0.44% → 1.41% (+0.97%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$3.39M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$421K |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$291K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$103K |
| 5 |
Jane Street
New York
|
+$9.05K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$50.8K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$48.5K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$42.1K |
| 4 |
VF
Virtu Financial
New York
|
-$30K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$9.53K |
NRXP Hedge Fund Activity: Q2 2023 in Review
32 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q2 2023, worth a combined $4.78M — up 131% from $2.07M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new NRXP positions and 4 closed out — a net gain of 2 holders — while 6 added to existing stakes and 5 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $3.39M. The largest seller was BlackRock, cutting an estimated $50.8K.
- 32 institutional investors held NRX Pharmaceuticals (NRXP) as of Q2 2023, up from 30 in Q1 2023.
- Funds reported $4.78M of NRX Pharmaceuticals stock for Q2 2023, up 131% quarter-over-quarter.
- 6 funds opened new NRX Pharmaceuticals positions in Q2 2023 and 4 closed out, a net change of +2 holders.
- The largest NRX Pharmaceuticals buyer in Q2 2023 was Armistice Capital, an estimated $3.39M added.
- The largest NRX Pharmaceuticals seller in Q2 2023 was BlackRock, an estimated $50.8K sold.
Based on aggregated 13F filings for Q2 2023.